RBC Capital Lifts Gilead Sciences (GILD) PT to $95 On Insights From a 2022 Patient Survey

By Yahoo! Finance | 1 month ago

Gilead Sciences Inc. (NASDAQ:GILD) is identified as a top NASDAQ stock to invest in, with potential growth driven by new drug lenacapavir. Despite Q1 revenue missing estimates, the company remains confident in its full-year guidance.

Did you find this insightful?